PolyPid (NASDAQ:PYPD) Posts Earnings Results, Beats Expectations By $0.01 EPS

PolyPid (NASDAQ:PYPDGet Rating) announced its earnings results on Wednesday. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01, MarketWatch Earnings reports. During the same quarter in the previous year, the firm earned ($0.47) earnings per share.

Shares of PolyPid stock traded up $0.20 on Thursday, reaching $4.77. 74,284 shares of the stock were exchanged, compared to its average volume of 40,629. PolyPid has a 1-year low of $3.92 and a 1-year high of $9.64. The business has a fifty day moving average price of $5.21 and a two-hundred day moving average price of $5.69. The firm has a market capitalization of $81.31 million, a PE ratio of -2.10 and a beta of 0.83.

Several institutional investors have recently modified their holdings of PYPD. Morgan Stanley acquired a new position in shares of PolyPid during the second quarter worth about $32,000. Millennium Management LLC grew its position in PolyPid by 153.5% during the second quarter. Millennium Management LLC now owns 56,530 shares of the company’s stock worth $512,000 after buying an additional 34,227 shares during the period. Geode Capital Management LLC grew its position in PolyPid by 12.2% during the third quarter. Geode Capital Management LLC now owns 12,545 shares of the company’s stock worth $97,000 after buying an additional 1,364 shares during the period. UBS Group AG grew its position in PolyPid by 32.7% during the third quarter. UBS Group AG now owns 204,555 shares of the company’s stock worth $1,592,000 after buying an additional 50,395 shares during the period. Finally, Bank of America Corp DE acquired a new position in PolyPid during the fourth quarter worth about $52,000. Institutional investors and hedge funds own 20.84% of the company’s stock.

PYPD has been the subject of a number of research reports. Raymond James reduced their target price on shares of PolyPid from $23.00 to $17.00 and set a “strong-buy” rating for the company in a report on Friday, February 11th. Zacks Investment Research raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Wednesday, April 13th.

PolyPid Company Profile (Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.

See Also

Earnings History for PolyPid (NASDAQ:PYPD)

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.